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OPEN ACCESS
Ketamine modulates subgenual cingulate
connectivity with the memory-related
neural circuit—a mechanism of relevance
to resistant depression?
Jing J. Wong, Owen O’Daly, Mitul A. Mehta, Allan H. Young and James M. Stone
Institute of Psychiatry, Psychology and Neuroscience, King’s College London, University of London, London,
United Kingdom
ABSTRACT
Background. Ketamine has been reported to have efficacy as an antidepressant in
several studies of treatment-resistant depression. In this study, we investigate whether
an acute administration of ketamine leads to reductions in the functional connectivity
of subgenual anterior cingulate cortex (sgACC) with other brain regions.
Methods. Thirteen right-handed healthy male subjects underwent a 15 min resting
state fMRI with an infusion of intravenous ketamine (target blood level = 150 ng/ml)
starting at 5 min. We used a seed region centred on the sgACC and assessed functional
connectivity before and during ketamine administration.
Results. Before ketamine administration, positive coupling with the sgACC seed
region was observed in a large cluster encompassing the anterior cingulate and
negative coupling was observed with the anterior cerebellum. Following ketamine
administration, sgACC activity became negatively correlated with the brainstem,
hippocampus, parahippocampal gyrus, retrosplenial cortex, and thalamus.
Discussion.Ketamine reduced functional connectivity of the sgACCwith brain regions
implicated in emotion, memory and mind wandering. It is possible the therapeutic
effects of ketamine may be mediated via this mechanism, although further work is
required to test this hypothesis.
Subjects Neuroscience, Psychiatry and Psychology, Radiology and Medical Imaging,
Computational Science
Keywords Ketamine, Depression, Anterior cingulate, Antidepressant, MRI
INTRODUCTION
The subgenual anterior cingulate (sgACC), or Brodmann area 25, is a brain region that
has been implicated in the control and modulation of mood. Decreased mean sgACC
gray matter volume combined with metabolic hyperactivity and hyperconnectivity has
been observed in patients with major depressive disorder (MDD) (Davey et al., 2012;
Drevets, Savitz & Trimble, 2008; Greicius et al., 2007; Sundermann, Olde Lutke Beverborg
& Pfleiderer, 2014). With a growing number of studies demonstrating the association
between metabolic hyperactivity in this region and poor therapeutic response (Baeken
et al., 2014; Konarski et al., 2009;Maletic & Raison, 2009; Sheline et al., 2010; Taylor &
Liberzon, 2007), the activity of this region may prove important for attempts to predict
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treatment response in patients (Siegle et al., 2012). Furthermore, given that connectivity
between the sgACC and the default mode network (particularly the ventromedial
prefrontal cortex, and posterior cingulate cortex) has been hypothesised to underlie
depressive rumination (Hamilton et al., 2015), therapeutic disruption of this connectivity
might also be a potential target for novel antidepressant action.
Treatment resistant depression (TRD) is common, with approximately 45% of patients
failing to respond to pharmacological treatment (Papakostas & Fava, 2010). Currently
available antidepressants are characterised by a relatively slow onset of effect ranging from
weeks to months. There has been great interest in the potential of ketamine as a treatment
for TRD patients, given early reports of strong and rapid (within hours) antidepressant
properties in patients otherwise resistant to antidepressant treatment (Fond et al., 2014;
Salvadore et al., 2009; Zarate et al., 2012; Zarate et al., 2006).
Ketamine has been reported to reduce sgACC activity in healthy volunteers (De Simoni
et al., 2013; Deakin et al., 2008; Doyle et al., 2013; Stone et al., 2015), and responders to ke-
tamine with treatment resistant bipolar depression have been reported to have increased
glucose metabolism in this region (Nugent et al., 2014). However, the effect of ketamine
on subgenual connectivity, which might be hypothesised to underlie its antidepressant
effects, has not been fully investigated. To date there has only been one study on the effect
of ketamine on brain connectivity in relation to potential antidepressant mechanisms.
Ketamine was shown to disrupt connectivity between the sgACC and the dorsal nexus
24 h following administration in healthy volunteers, an effect that was hypothesised to
be related to its antidepressant properties (Scheidegger et al., 2012). We hypothesise that
immediate effects of ketamine might also play an important part in the therapeutic effects
of ketamine in TRD, and that the early modulation of circuits involved in maintenance
of depressive cognitions may be necessary for the emergence of objectively measureable
clinical improvement.
In this study, which is an analysis of existing resting state data (Stone et al., 2015),
we investigated the effect of acute intravenous ketamine administration on functional
connectivity of the sgACC in healthy volunteers.
MATERIALS AND METHODS
The study was approved by the East London Research Ethics Committee. Prior to screening
for the study, all participants gave written informed consent for inclusion. Inclusion criteria:
healthy right-handedmale subjects (18–50 years old) with a total body weight of 50–100 kg.
Exclusion criteria: positive urine drug screen for drugs of abuse, the consumption of more
than 5 cups of coffee per day, smoking more than 5 cigarettes per day, taking prescription
drugs, and any history of mental illness, or serious medical condition that, in the opinion
of the study doctors, prevented their participation in the study.
Thirteen healthy, right handed, male volunteers (age 21–39, mean 27, standard deviation
6.90) were selected for the study after screening. Each subject underwent medical, mental
state, physical, and psychiatric examination including electrocardiogram, urine drug screen,
and taking measurements of blood pressure, pulse rate, temperature, and weight. Each
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volunteer underwent venous cannulation in the left antecubital fossa. We attached a 50 ml
syringe pump containing 4 mg/ml racemic ketamine via an infusion line.
Image acquisition was conducted, as previously reported (Stone et al., 2015), at the
Centre for Neuroimaging Sciences on a General Electric (Milwaukee, Wisconsin) 3-Tesla
HDxMRI scanner. Pharmacological MRI (phMRI) blood-oxygen level dependent (BOLD)
data were acquired using gradient echo EPI (Echo-Planar Imaging) with parallel imaging
accelerated by a factor of 2. Each participant was scanned continuously for 15 min to yield
a total of 450 functional image volumes of 37, continuous top down, 3 mm thick slices
with a slice gap of 0.3 mm, repeat time (TR) of 2000 ms, echo time (TE) of 30 ms, flip angle
of 75◦, in-plane resolution of 3.3 mm, 64 × 64 matrix, and 21.1 × 21.1 cm field of view.
The ketamine infusion commenced after 5 min of resting state acquisition and followed
a dynamically modelled intravenous infusion with a target plasma level of 150 ng/mL
determined according to pharmacodynamic properties of ketamine from the ‘‘Clements
250model’’, with a rapid bolus over 20 s of approximately 0.26mg/Kg, on average, followed
by a slow infusion of approximately 0.42 mg/Kg/Hr. Participants’ peak ketamine-induced
experience was rated by a trained psychiatrist using the positive and negative syndrome
scale (PANSS) immediately following their exit from the scanning room.
Preprocessing and statistical analyses were performed using Statistical Parametric
Mapping software version 8 (SPM8; Wellcome Trust Centre for Neuroimaging, London,
England). Functional images were corrected for slice timing effects and subsequently
realigned to correct for the effects of volume-to-volume head motion. Data were examined
to confirm that framewise translational and rotational head movement did not exceed
2 mm or 1◦. Images were co-registered to a high-resolution T1-weighted structural image,
and normalised to Montreal Neurological Institute (MNI) space via unified segmentation.
The normalised images were smoothed using an 8 mm full width at half maximum
(FWHM) Gaussian kernel. Additional preprocessing was carried out using the REST
toolbox for resting state fMRI analysis (Song et al., 2011). Nuisance variables such as
motion parameters (volume to volume translations in 3 axes and rotation around these
axes), white matter and CSF signal were regressed from the data. The residual time-series
was then de-trended and band-pass filtered (frequency range 0.01–0.08 Hz) and a signal
time-series was extracted from the sgACC seed (10 mm sphere at [2, 28, −5] based upon
a previous publication (Scheidegger et al., 2012)). The 15-minute time series was separated
into three 5-minute time-series segments of pre-infusion, early-infusion and late-infusion.
The early-infusion portion of the time series was disregarded as any observed connectivity
would have been dominated by the phMRI response to the bolus. Finally, connectivity
maps between the sgACC seed and the whole brain were created using regression within
the REST toolbox, and the resultant r-maps underwent r-to-Z conversion again within
REST.
These Z -transformed maps were taken forward into a second level random effect
analysis within SPM8. A one sample t -test was used to characterise sgACC connectivity
prior to ketamine administration, and a paired t -test was employed (comparing pre- and
post-ketamine connectivity) to identify regional changes in sgACC coupling following
ketamine administration. We also directly investigated connectivity between the sgACC
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Table 1 Resting state sgACC coupling prior to ketamine administration. Regions showing significant coupling with sgACC prior to ketamine in-
fusion (pFWE < 0.05 corrected for multiple comparisons on the basis of cluster extent, using a cluster-forming threshold of z = 3.1).
sgACC coupling Brain region Brodmann area Cluster-level Peak-level Coordinates
pFWE kE (Zo) x y z
Positive Ventral Anterior Cingulate 24 <0.001 12,610 6.69 4 27 −6
Positive Dorsal Anterior Cingulate 32 6.23 −6 35 −3
Positive Thalamus 5.79 −2 −3 −3
Negative Anterior Cerebellum <0.001 3,705 4.69 −12 −37 −27
Negative Pons 4.16 9 −22 −24
Negative Anterior Cerebellum 3.96 10 −37 −26
Negative Middle Frontal Gyrus 9 <0.001 1,089 4.68 43 12 33
Negative Middle Frontal Gyrus 9 4.50 42 3 39
Negative Precentral Gyrus 6 4.03 51 0 40
Negative Superior Frontal Gyrus 10 0.001 971 4.45 22 51 24
Negative Middle Frontal Gyrus 9 4.12 34 29 28
Negative Middle Frontal Gyrus 9 3.77 30 36 21
Negative Inferior Parietal Lobule 40 0.007 649 4.17 66 −46 31
Negative Inferior Parietal Lobule 40 3.46 70 −46 22
Negative Postcentral Gyrus 2 3.44 61 −30 43
seed and the dorsal nexus region, by use of two spherical masks of 10 mm radius at
x =±36, y = 27, z = 29 (Sheline et al., 2010). Results were considered significant if they
survived family wise error (FWE) correction on the basis of cluster-extent (pFWE < 0.05).
The PANSS general score was tested for normality using the Shapiro–Wilk test prior to
regression analysis against ketamine-induced change in sgACC connectivity.
RESULTS
Prior to ketamine administration, there was positive coupling (pFWE < 0.05) between
sgACC and multiple brain regions including anterior cingulate, ventral striatum, and
thalamus. Therewas negative coupling (pFWE < 0.05) between sgACC and regions including
cerebellum, pons, precentral gyrus, superior frontal gyrus, and parahippocampus (Table 1).
Following ketamine administration, there was significant reduction in sgACC coupling
with a large cluster including the hippocampus, retrosplenial cortex (RSC), and thalamus
centred at [−2 −3 6] (pFWE= 0.002; kE = 2,885; Zo= 3.69) (Fig. 1). Plotting the contrast
estimate from the cluster peak, located in the retrosplenial cortex [−6−55 3], revealed that
the RSC was uncorrelated with the sgACC before ketamine administration, but that it was
negatively correlated with the sgACC following ketamine administration (Fig. 2). There
was no significant change in connectivity between sgACC and the dorsal nexus region
following ketamine administration.
Ketamine administration was associated with a mean (SD) increase in PANSS positive,
negative, and general subscales to 10.7(2.89), 10.07(3.43), and 20.15(3.53) respectively
(p< 0.05). Multiple regression analysis using cluster forming threshold of p< 0.01 was
performed to test for correlations between changes in whole brain functional connectivity
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Figure 1 sgACC connectivity following ketamine administration. Regions showing significant (pFWE <
0.05) reduction in sgACC coupling following ketamine administration (red/yellow).
Figure 2 Effect of ketamine on connectivity between sgACC and retrosplenial cortex. Correlation be-
tween sgACC and retrosplenial cortex [−6−55 3] before and after the start of ketamine administration.
with sgACC following ketamine administration and PANSS scores. No correlations with
PANSS positive or negative scores were found, but a negative correlation between the
PANSS general score and sgACC coupling was observed in the medial prefrontal cortex
(mPFC) and subcallosal gyrus (SCG) (pFWE < 0.05). In order to further investigate
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Figure 3 Correlation between PANSS depression and sgACC coupling. Regions showing significant
(pFWE < 0.05) correlations between PANSS depression score and change in sgACC coupling following ke-
tamine administration (blue—negative correlation, yellow—positive correlation).
this correlation, we performed a post-hoc analysis of the correlation between sgACC
coupling and depression-related items using the 5 factor PANSS (Lindenmayer, Bernstein-
Hyman & Grochowski, 1994). The level of the depression subscale (primarily anxiety and
preoccupation rather than the depression item) was significantly increased following
ketamine administration (p< 0.05), and was found to be negatively associated with
coupling between sgACC and subcallosal gyrus and with right ventrolateral prefrontal
cortex (pFWE < 0.05). The depression subscale was positively associated with coupling
between sgACC and right ventromedial prefrontal cortex (pFWE < 0.05; Fig. 3).
DISCUSSION
In this study, we examined the acute effect of ketamine on functional connectivity between
the sgACC and other brain regions. Our primary aim was to investigate the effect of
acute ketamine administration in healthy volunteers on brain networks hypothesised
to be involved in the aetiopathology of depression. The most striking effect of acute
ketamine administration in this study is the disruption of connectivity between sgACC
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and a large cluster encompassing midline thalamus, hippocampus, RSC. This may be
of relevance to the antidepressant effect. Both thalamus and hippocampus have been
implicated in the pathology of MDD (Malykhin & Coupland, 2015; Yakovlev et al., 1960;
Young et al., 2004). Furthermore, the network connectivity between sgACC and the default
mode network, including RSC is increased in patients with MDD, and has been suggested
to underlie depressive ruminations (Hamilton et al., 2015), a process hypothesized to
be of great significance in the maintenance of depressed mood (Disner et al., 2011). If
ketamine is able to disrupt the tendency of the mind to return to depressive ruminations
through changing the functional connectivity within this network, this may be of particular
importance in its antidepressant action. Interestingly, two studies of ketamine effects on
functional connectivity revealed an increase rather than a decrease in connectivity between
hippocampus and prefrontal cortex following ketamine administration (Gass et al., 2014;
Grimm et al., 2015). In addition a graph theory analysis of whole brain connectivity
showed a pattern of increased subcortical/cerebellar connectivity after ketamine in
healthy volunteers (Joules et al., 2015). It is worth noting, however, that these studies
did not specifically examine connectivity with sgACC, and it is possible that a decrease in
connectivity may have been seen between this region and the hippocampus.
Although ketamine acutely increased rather than decreased scores on the 5 factor PANSS
depression scale in this healthy volunteer sample (it would not have been possible to for
depressive scores to reduce as volunteers did not have any symptoms before ketamine
administration) it is notable that changes in functional connectivity between subgenual
anterior cingulate and other brain regions correlated only with the general and depressive
scores on the PANSS, and not with positive or negative subscales. Our finding of a
correlation between ketamine-induced increases on the depression subscale and reduced
sgACC coupling with surrounding regions of the SCG is of interest as the SCG is an
important node in a neural network comprising of cortical structures, the limbic system,
thalamus, hypothalamus, and brainstem nuclei. MDD patients generally show increased
activity in SCG, which is normalised by antidepressant treatment (Hamani et al., 2011).
It is possible that this local reduction in connectivity reflects a direct consequence of
the reduced BOLD activity in this brain region seen following ketamine administration
(Stone et al., 2015).
It is interesting that we found a reduction in connectivity between sgACC and
ventrolateral prefrontal cortex associated with increases in ketamine-induced scores on
the depression subscale, whereas there was an associated increase in connectivity between
sgACC and ventromedial prefrontal cortex connectivity with the same scale. The reason
for this is not entirely clear, but both ventrolateral and ventromedial prefrontal cortices
have been implicated in depression (Ma et al., 2013; Miller et al., 2015). Ventromedial
prefrontal cortex connectivity with sgACC has been suggested to underlie depressive
ruminations (Hamilton et al., 2015), so the fact that ketamine acutely increased depression
scores and increased this connectivity is in keeping with this finding. In contrast, one study
in patients with treatment resistant unipolar depression found increases in connectivity
between anterior cingulate cortex and a cluster including ventrolateral prefrontal cortex
associated with clinical response to transcranial magnetic stimulation (Baeken et al., 2014),
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and thus decreases in connectivity between these two regions might be predicted to increase
depressive symptoms. However, it is not at all clear how ketamine-induced increases in
depression scores in healthy volunteers may be related to its effect as an antidepressant in
patients with existing clinical depression.
There are a number of limitations regarding the study design. The fact we were studying
healthy volunteers means that any effects we see in functional connectivity may not map
directly onto those that occur in patients with MDD. Ketamine modulation of brain
circuits may vary according to severity of depression and thus networks affected in healthy
controls may be different to those suffering from MDD. Related to this, we were not able
to measure the antidepressant effect of ketamine as the volunteers had no measureable
depressive symptoms at presentation, and so the current data cannot provide evidence that
ketamine-induced changes in connectivity are related to ketamine’s antidepressant effect.
Secondly, the effects investigated in the present study occurred 5 min following ketamine
administration, during the steady-state infusion, whereas antidepressant effect in patients
do not normally arise until 40 min to 2 h after ketamine administration. We hypothesise
that the changes reported in the current study may be precursors to an antidepressant
effect, but it is possible that changes in functional connectivity relevant to antidepressant
mechanism between other brain regions might arise at later time points. Lastly, we did not
have a placebo arm. However, participants were not aware when the ketamine was started,
and our earlier placebo-controlled study using an identical method of ketamine infusion
did not show any effect of placebo on BOLD signal in any brain region (Doyle et al., 2013).
CONCLUSION
We found that ketamine alters the functional connectivity of the sgACC in healthy controls.
The networks affected suggest that these changes may be of importance in the therapeutic
effects of ketamine in patients withMDD. Further studies in patients are required to test the
hypothesis that ketamine may reduce depressive rumination via acute effects on sgACC-
RSC connectivity.
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